CLIMB BIO INC
CLYMNASDAQTrading Snapshot
- Day Range
- $390.69 – $401.62
- 52-Week Range
- $1.54 – $18.33
- Volume
- $3.61B
- Avg Volume
- $2.89B
- Shares Outstanding
- 57.3M
- Next Earnings
- Nov 18, 2026
Fundamentals Snapshot
- Annual Revenue
- $52M
- Last Q Revenue
- $14M
- P/E Ratio
- -13.9
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.76
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +4.1%
Why Investors Own CLYM
- ✓High-growth profile — revenue up +50.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 48% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CLIMB BIO INC
CLYM
StockOtter · stockotter.spaceAbout CLIMB BIO INC
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
Climb Bio NASDAQ: CLYM presented phase I data for CLYM116, an anti-APRIL “sweeper” antibody being developed for IgA nephropathy, and said the results support advancing the program into an ongoing phase II study in China.
Climb Bio's Kidney Disease Therapy Gets Support for Extended Dosing Schedule
Climb Bio Inc. (NASDAQ:CLYM) on Thursday released preliminary data from its ongoing Phase 1 trial assessing CLYM116, while revealing updated strategic plans for treating IgA nephropathy, a kidney disease.
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse events, dose-limiting to
Climb Bio to Present at Upcoming Investor Conferences
WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that m
Climb Bio (NASDAQ:CLYM) Shares Up 10.9% Following Analyst Upgrade
Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report) shot up 10.9% on Monday after Wedbush raised their price target on the stock from $17.00 to $20.00. Wedbush currently has an outperform rating on the stock. Climb Bio trad
Climb Bio (NASDAQ:CLYM) Sets New 52-Week High Following Analyst Upgrade
Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report)'s stock price reached a new 52-week high during trading on Tuesday after Wedbush raised their price target on the stock from $17.00 to $20.00. Wedbush currently has an out